This website is optimized for visualization with Firefox and Internet Explorer (8 or 9)

CLINICAL DEVELOPMENT PIPELINE

Regulatory Review

Phase III

Phase II

  • Prexasertib (prex” a ser’ tib)
    LY2606368 monomesylate monohydrate (formerly known as Chk1 inhibitor) is a chemical entity that preferentially binds to and inhibits checkpoint kinase 1 (Chk1), a global regulator of the mammalian cell cycle and, to a lesser extent, inhibits Chk2. LY2606368 monomesylate monohydrate is being studied for the treatment of cancer.

    For more information on LY2606368 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • CXCR4 Peptide Antagonist
    LY2510924 (CXCR4 peptide antagonist) is a biologic entity that antagonizes ligand binding to the CXC chemokine receptor 4. LY2510924 is being studied for the treatment of cancer.

    For more information on LY2510924 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Emibetuzumab (em” i be tooz’ ue mab)
    LY2875358 (formerly known as c-Met antibody), a biologic entity, was designed as a bivalent c-Met antibody that has neutralization and internalization activity with minimal agonistic activity. LY2875358 is being studied for the treatment of NSCLC.

    For more information on LY2875358 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • FGF Receptor Inhibitor
    LY2874455 (FGF receptor inhibitor), a chemical entity, inhibits autophosphorylation of fibroblast growth factor (FGF) receptors 1, 2, 3 and 4, which is required for activation of FGF-induced downstream signaling. LY2874455 is being studied for the treatment of cancer.

    For more information on LY2874455 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Galunisertib (gal ue” ni ser’ tib)
    LY2157299 monohydrate (formerly known as TGFb R1 kinase inhibitor) is a chemical entity that selectively blocks transforming growth factor-β receptor I kinase and TGF-b signaling. LY2157299 monohydrate is being studied for the treatment of pancreatic and hepatocellular cancer.

    For more information on LY2157299 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Merestinib cancer (mer es’ ti nib)
    LY2801653 (formerly known as c-Met inhibitor) is a chemical entity that has been shown in vitro to be a reversible type II ATP-competitive inhibitor of MET, a receptor for hepatocyte growth factor. Preclinical testing also has shown LY2801653 to inhibit several other receptor tyrosine oncokinases including MST1R, FLT3, AXL, MERTK, TEK, ROS1, and DDR1/2 and the serine/threonine kinases MKNK1/2. LY2801653 is being studied for the treatment of cancer.

    For more information on LY2801653 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • NOTCH inhibitor cancer
    LY3039478 (NOTCH Inhibitor) is a new chemical entity being studied for the treatment of cancer.

    For more information on LY3039478 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • PI3 Kinase/mTOR Dual Inhibitor
    LY3023414 (PI3 Kinase/mTOR dual Inhibitor) is a chemical entity being studied for the treatment of prostate cancer and NSCLC.

    For more information on LY3023414 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Ralimetinib (ral’’ i me’ ti nib)
    LY2228820 dimesylate (formerly known as p38 MAP kinase inhibitor) is a chemical entity that preferentially binds to and inhibits p38 MAP kinase. LY2228820 dimesylate is being studied for the treatment of ovarian cancer.

    For more information on LY2228820 dimesylate clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Abemaciclib (a be muh sī klib)
    LY2835219 (abemaciclib), a chemical entity, is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 that inhibits phosphorylation of the Rb tumor suppressor protein and thereby induces G1 cell cycle arrest. LY2835219 is being studied for the treatment of squamous NSCLC.

    For more information on LY2835219 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Phase I

  • Angiopoietin 2 MAb cancer
    "Angiopoietin 2 Antibody" is a new biologic entity being studied for the treatment of cancer.

     
  • Chk1 Inhibitor
    "Chk1 Inhibitor" is a new chemical entity being studied for the treatment of cancer. Molecule is owned by a 3rd party, Lilly retains rights.

     
  • CSF-1R Monoclonal Antibody
    "CSF-1R Monoclonal Antibody" is a new biologic entity being studied for the treatment of cancer.

     
  • FGFR3-ADC cancer
    "FGFR3-ADC" is a new biologic entity being studied for the treatment of cancer.

     
  • Met/EGFR Bispecific Antibody
    "Met/EGFR Bispecific Antibody" is a new biologic entity being studied for the treatment of cancer.

     
  • Pan-Raf inhibitor
    "Pan-Raf inhibitor" is a new chemical entity being studied for the treatment of cancer.

     
  • PD-L1 Antibody
    "PD-L1 Antibody" is a new biologic entity being studied for the treatment of cancer.

     
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Pipeline Disclaimer
The information included on this site reflects Eli Lilly and Company's clinical development pipeline and is not intended for promotional purposes. It includes both new molecular entities as well as select new indications or line extensions of currently-approved products, that are in clinical development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued, delayed or fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information is current as of July 19, 2016. Lilly assumes no duty to update this information.

For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being studied is listed.
  • NME
  • Select NILEX
  • Diagnostic